We addressed this issue through further analysis; hsa_circ_0026817-hsa-miR-211-5p-CACNA1C, hsa_circ_0007215-hsa-miR-1343-3p-RBL1, and hsa_circ_0007215-hsa-miR-1252-5p-MECP2 may be a new effective and potential target for the treatment of CAVD. This evidence concerns the gene MECP2 and congenital bilateral aplasia of vas deferens from CFTR mutation.